319 related articles for article (PubMed ID: 37370032)
21. ACRNaCT trial protocol: efficacy of adjuvant chemotherapy in patients with clinical T3b/T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: a pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial.
Li Q; Luo D; Zhu J; Yang L; Liu Q; Ma Y; Liang L; Cai S; Zhang Z; Li X;
BMC Cancer; 2019 Nov; 19(1):1117. PubMed ID: 31729964
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab and Combination Chemotherapy in rectal cancer Until Surgery (BACCHUS): a phase II, multicentre, open-label, randomised study of neoadjuvant chemotherapy alone in patients with high-risk cancer of the rectum.
Glynne-Jones R; Hava N; Goh V; Bosompem S; Bridgewater J; Chau I; Gaya A; Wasan H; Moran B; Melcher L; MacDonald A; Osborne M; Beare S; Jitlal M; Lopes A; Hall M; West N; Quirke P; Wong WL; Harrison M;
BMC Cancer; 2015 Oct; 15():764. PubMed ID: 26493588
[TBL] [Abstract][Full Text] [Related]
23. Retrospective Comparison of mFOLFOXIRI With XELOX/SOX as Neoadjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kodama H; Terazawa T; Ishizuka Y; Yukami H; Aoki M; Miyamoto T; Yamaguchi T; Shimamoto F; Kii T; Goto M; Hamamoto H; Osumi W; Yamamoto M; Tanaka K; Okuda J; Uchiyama K; Higuchi K
In Vivo; 2021; 35(2):977-985. PubMed ID: 33622892
[TBL] [Abstract][Full Text] [Related]
24. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
[TBL] [Abstract][Full Text] [Related]
25. [Short-course radiotherapy combined with CAPOX and PD-1 inhibitor for the total neoadjuvant therapy of locally advanced rectal cancer: the preliminary single-center findings of a prospective, multicentre, randomized phase II trial (TORCH)].
Wang YQ; Shen LJ; Wan JF; Zhang H; Wang Y; Wu X; Wang JW; Wang RJ; Sun YQ; Tong T; Huang D; Wang L; Sheng WQ; Zhang X; Cai GX; Xu Y; Cai SJ; Zhang Z; Xia F
Zhonghua Wei Chang Wai Ke Za Zhi; 2023 May; 26(5):448-458. PubMed ID: 37217353
[No Abstract] [Full Text] [Related]
26. A prospective, single-arm, multicenter trial of neoadjuvant chemotherapy with mFOLFOX6 plus panitumumab without radiotherapy for locally advanced rectal cancer.
Toritani K; Watanabe J; Suwa Y; Nakagawa K; Suwa H; Ishibe A; Ota M; Kunisaki C; Yamanaka T; Endo I
Int J Colorectal Dis; 2020 Dec; 35(12):2197-2204. PubMed ID: 32725346
[TBL] [Abstract][Full Text] [Related]
27. Non-operative management after chemoradiotherapy plus consolidation or sandwich (induction with bevacizumab and consolidation) chemotherapy in patients with locally advanced rectal cancer: a multicentre, randomised phase II trial (NOMINATE trial).
Akiyoshi T; Shinozaki E; Taguchi S; Chino A; Hiratsuka M; Tominaga T; Nonaka T; Toda S; Matoba S; Matsui S; Okabayashi K; Mukai T; Hiyoshi Y; Yamaguchi T; Nagasaki T; Yamaguchi K; Ueno M; Kuroyanagi H; Fukunaga Y; Ishizuka N; Konishi T;
BMJ Open; 2022 Mar; 12(3):e055140. PubMed ID: 35304396
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial.
Conroy T; Bosset JF; Etienne PL; Rio E; François É; Mesgouez-Nebout N; Vendrely V; Artignan X; Bouché O; Gargot D; Boige V; Bonichon-Lamichhane N; Louvet C; Morand C; de la Fouchardière C; Lamfichekh N; Juzyna B; Jouffroy-Zeller C; Rullier E; Marchal F; Gourgou S; Castan F; Borg C;
Lancet Oncol; 2021 May; 22(5):702-715. PubMed ID: 33862000
[TBL] [Abstract][Full Text] [Related]
29. Survival After Induction Chemotherapy and Chemoradiation Versus Chemoradiation and Adjuvant Chemotherapy for Locally Advanced Rectal Cancer.
Kim JK; Marco MR; Roxburgh CSD; Chen CT; Cercek A; Strombom P; Temple LKF; Nash GM; Guillem JG; Paty PB; Yaeger R; Stadler ZK; Gonen M; Segal NH; Reidy DL; Varghese A; Shia J; Vakiani E; Wu AJ; Romesser PB; Crane CH; Gollub MJ; Saltz L; Smith JJ; Weiser MR; Patil S; Garcia-Aguilar J
Oncologist; 2022 May; 27(5):380-388. PubMed ID: 35278070
[TBL] [Abstract][Full Text] [Related]
30. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
[TBL] [Abstract][Full Text] [Related]
31. Consolidation mFOLFOX6 Chemotherapy After Chemoradiotherapy Improves Survival in Patients With Locally Advanced Rectal Cancer: Final Results of a Multicenter Phase II Trial.
Marco MR; Zhou L; Patil S; Marcet JE; Varma MG; Oommen S; Cataldo PA; Hunt SR; Kumar A; Herzig DO; Fichera A; Polite BN; Hyman NH; Ternent CA; Stamos MJ; Pigazzi A; Dietz D; Yakunina Y; Pelossof R; Garcia-Aguilar J;
Dis Colon Rectum; 2018 Oct; 61(10):1146-1155. PubMed ID: 30192323
[TBL] [Abstract][Full Text] [Related]
32. Phase II Trial of Neoadjuvant Chemotherapy, Chemoradiotherapy, and Laparoscopic Surgery with Selective Lateral Node Dissection for Poor-Risk Low Rectal Cancer.
Konishi T; Shinozaki E; Murofushi K; Taguchi S; Fukunaga Y; Nagayama S; Fujimoto Y; Akiyoshi T; Nagasaki T; Suenaga M; Chino A; Kawachi H; Yamamoto N; Ishikawa Y; Oguchi M; Ishizuka N; Ueno M; Yamaguchi K
Ann Surg Oncol; 2019 Aug; 26(8):2507-2513. PubMed ID: 30963400
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of neoadjuvant IMRT-based chemoradiotherapy followed by one cycle of capecitabine for stage II/III rectal adenocarcinoma.
Zhu J; Gu W; Lian P; Sheng W; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2013 May; 8():130. PubMed ID: 23718210
[TBL] [Abstract][Full Text] [Related]
34. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
35. [Comparison of long-term efficacy between watch and wait strategy and total mesorectal excision in locally advanced rectal cancer patients with clinical complete response after neoadjuvant therapy].
Wang XH; Zhou CJ; Zhang S; Wang QX; Xiao WW; Ding PR; Chen G; Pan ZZ; Zeng ZF; Gao YH
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):266-273. PubMed ID: 32192306
[No Abstract] [Full Text] [Related]
36. Use of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Initial Results From the Pembrolizumab Arm of a Phase 2 Randomized Clinical Trial.
Rahma OE; Yothers G; Hong TS; Russell MM; You YN; Parker W; Jacobs SA; Colangelo LH; Lucas PC; Gollub MJ; Hall WA; Kachnic LA; Vijayvergia N; O'Rourke MA; Faller BA; Valicenti RK; Schefter TE; George S; Kainthla R; Stella PJ; Sigurdson E; Wolmark N; George TJ
JAMA Oncol; 2021 Aug; 7(8):1225-1230. PubMed ID: 34196693
[TBL] [Abstract][Full Text] [Related]
37. Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T; Gunderson AJ; Gilchrist M; Whiteford M; Kiely MX; Hayman A; O'Brien D; Ahmad R; Manchio JV; Fox N; McCarty K; Phillips M; Brosnan E; Vaccaro G; Li R; Simon M; Bernstein E; McCormick M; Yamasaki L; Wu Y; Drokin A; Carnahan T; To Y; Redmond WL; Lee B; Louie J; Hansen E; Solhjem MC; Cramer J; Urba WJ; Gough MJ; Crittenden MR; Young KH
Lancet Oncol; 2022 Sep; 23(9):1189-1200. PubMed ID: 35952709
[TBL] [Abstract][Full Text] [Related]
38. Concomitant boost IMRT-based neoadjuvant chemoradiotherapy for clinical stage II/III rectal adenocarcinoma: results of a phase II study.
Zhu J; Liu F; Gu W; Lian P; Sheng W; Xu J; Cai G; Shi D; Cai S; Zhang Z
Radiat Oncol; 2014 Mar; 9():70. PubMed ID: 24606870
[TBL] [Abstract][Full Text] [Related]
39. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
[TBL] [Abstract][Full Text] [Related]
40. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study.
Yu X; Wang QX; Xiao WW; Chang H; Zeng ZF; Lu ZH; Wu XJ; Chen G; Pan ZZ; Wan DS; Ding PR; Gao YH
Cancer Commun (Lond); 2018 May; 38(1):24. PubMed ID: 29784042
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
